Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Delayed H. pylori eradication retreatment ups subsequent upper GI bleeding risk

05 May 2020

Patients who have failed initial Helicobacter pylori eradication therapy are at heightened risk of upper gastrointestinal bleeding (UGIB), with the risk increasing progressively with longer time until retreatment, according to a recent study.

Researchers reviewed the medical records of 70,518 patients (median age, 54 years; 46.3 percent male) with H. pylori infection in Hong Kong who had received their first course of clarithromycin-based triple therapy, among whom 8,330 (11.8 percent) required retreatment after failed initial therapy. The median follow-up duration was 7.65 years.

Of the patients who failed initial therapy, 1,173 (1.7 percent), 2,162 (3.1 percent) and 4,995 (7.1 percent) received retreatment with a delay of ≤3, 3–12 and >12 months, respectively. Majority of the patients (85.6 percent) underwent one course of retreatment only.

Cox proportional hazard analysis revealed that patients who did vs did not require retreatment had an overall higher risk of UGIB, even after receipt of last eradication therapy (adjusted hazard ratio [HR], 1.50, 95 percent confidence interval [CI], 1.34–1.69).

Moreover, the risk of UGIB increased progressively with longer time between initial and final eradication therapies. A delay in retreatment of <3, 3–12 and >12 months increased the risk by 16 percent (HR, 1.16, 95 percent CI, 0.88–1.54), 35 percent (HR, 1.35, 95 percent CI, 1.07–1.69) and 68 percent (HR, 1.68, 95 percent CI, 1.46–1.94), respectively (p=0.038).

In light of the findings, the researchers emphasized the importance of administering early retreatment, within 3 months preferably, in order to minimize subsequent UGIB risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.